HAS-1 genetic polymorphism in sporadic abdominal aortic aneurysm by Armani, Chiara et al.
Heart International 2009; volume 4:e1
[Heart International 2009; 4:e1] [page 1]
Abstract 
The  hyaluronan  synthase  1  (HAS-1)  gene
encodes a plasma membrane protein that syn-
thesizes  hyaluronan  (HA),  an  extracellular
matrix  molecule.  Accumulating  evidence
emphasizes the relevance of HA metabolism in
an increasing number of processes of clinical
interest, including abdominal aortic aneurysm
(AAA). The existence of aberrant splicing vari-
ants of the HAS-1 gene could partly explain the
altered  extracellular  matrix  architecture  and
influence various biological functions, result-
ing in progressive arterial wall failure in the
development of AAA. In the present study, we
assessed  the  hypothesis  that  HAS-1 genetic
833A/G polymorphism could be associated with
the risk of AAA by performing a case-control
association study, involving AAA patients and
healthy matched donors.
Introduction
Human abdominal aortic aneurysm (AAA)
is  the  most  common  type  of  aneurysm  in
humans. It is characterized by abnormal dila-
tion  of  the  aorta  and  is  associated  with
histopathological changes of the arterial wall.
Although  the  presence  of  atherosclerotic
lesions  is  a  common  feature  in  AAA,  the
destruction  of  the  arterial  wall  is  a  crucial
point in the development of aneurysm.
1
Effective matrix macromolecules, such as
elastin, collagen and glycosaminoglycans/pro-
teoglycans, are responsible for the integrity of
the arterial wall. Hyaluronan (HA) is a large,
nonsulfated  glycosaminoglycan  (GAG)  pro-
duced in the vasculature by smooth muscle
cells and endothelial cells. It is synthesized at
the  inner  face  of  the  cell  membrane  by
hyaluronan synthase (HAS) encoded by three
genes to different chromosome localizations,
2
followed by translocation to the outer surface
and the intercellular space. Each isoenzyme
synthesizes different sizes of HA molecules
that exhibit not completely overlapping func-
tions. 
3
Recent in vitro investigations have shown
that  HA  influences  important  cellular  func-
tions  such  as  proliferation,  migration  and
secretory capabilities.
4 Alterations in hyaluro-
nan  metabolism,  distribution  and  function
have been documented in many diseases e.g.
arthritis,  immune  and  inflammatory  disor-
ders,  pulmonary  and  vascular  diseases,  as
well as cancer.
5
There seems to exist a delicately regulated
balance between production and removal of
HA that is central to its biological functions
under  normal  conditions.  If  this  balance  is
disturbed, it has been hypothesized that dis-
ease  may  develop.
6 We  hypothesize  that
changes in HA content or aberrant variants of
HA make the wall more susceptible to athero-
sclerotic stimuli, thus contributing to the AAA
development.  We  therefore,  carried  out  a
case-control association study in order to ver-
ify the association between the 833A/G poly-
morphism,  located  on  an  exonic  splicing
enhancer motif of the HAS-1 gene, and risk of
AAA.
Materials and Methods
Sample collection
Blood was collected from 146 AAA patients
and 156 control subjects with a negative his-
tory of vascular diseases. Patients with con-
nective tissue disorders or known inflamma-
tory  or  malignant  disease  were  excluded.
Controls  were  collected  among  volunteer
healthy blood donors and among people hospi-
talized for traumatic accidents to avoid the
use of hospitalized controls. All samples were
collected  in  the  Cisanello  Hospital  of  Pisa
(Tuscany, Italy). The Ethics Committee of the
institution  approved  the  study.  Participants
gave  their  informed  consent  for  the  study,
according to the Helsinki declaration.
Clinical diagnosis of AAA was confirmed by
echographic and spiral computed tomograph-
ic (CT) scan evaluations. AAA was defined as
a focal dilation of the abdominal aorta at least
50%  larger  than  expected  normal  diameter
(antero-posterior and lateral aortic diameter
values were increased to 50.78±11.66 mm and
50.54±13.35  mm,  respectively).  All  AAAs
underwent surgical repair. 
We recorded demographic and clinical data
including  age,  gender,  BMI  (Body  Mass
Index),  smoking  habits  (S=smoker,  EX=ex-
smoker, NS=no smoker; patients were consid-
ered ex-smokers if they had stopped smoking
at  least  five  years  before  inclusion  in  the
study), the presence or absence of hypercho-
lesterolemia (defined as total plasma choles-
terol level ≥220 mg/dL or cholesterol-lowering
drug  therapy),  the  presence  or  absence  of
hypertension (defined as diastolic blood pres-
sure  >95  mmHg  and/or  systolic  blood  pres-
sure >160 mmHg), the presence or absence of
diabetes. Moreover, a detailed history of car-
diovascular  risk  factors  was  obtained  from
each patient.
DNA extraction and genotyping
Genomic  DNA  was  isolated  from  EDTA
blood samples by a modified salting-out pro-
cedure.
8 Allele-specific  oligonucleotide  PCR
(ASO-PCR) method was carried out for HAS-
1 single nucleotide polymorphism (SNP) 833
A/G genotyping in a 20 ʼL reaction mixture
and 1 U of Taq polymerase (Eurobio-Labtek,
FR). Primers of our own design were used: 5’-
GGGTTAAGGATCCGCACG-3’  (wild  type
allele),  5’-GGGTTAAGGATCCGCACA-3’
(mutant  allele)  and  5’-CCTTCCTCTCAAG-
CATCAGC-3’  (reverse)  for  each  reaction  at
0.5 ʼM. PCR was carried out for 40 cycles
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consisting of an initial denaturation step at
95°C for 15’ followed by 20 cycles at 95°C for
1’, 68°C for 30” (-1°C/cycle), 72°C for 1’5” and
to 20 cycles at 95°C for 1’, 51°C for 30”, 72°C
for 1’5”, with a final extension at 72°C for 10’.
The 178 base-pair (bp) PCR product was visu-
alized on a 2% agarose gel (Eurobio-Labtek,
FR) stained with ethidium bromide. 
Statistical analysis
We tested the Hardy-Weinberg equilibrium of
genotype distributions separately among case
patients and control subjects by ˇ
2 test. All the
covariates were analyzed by ˇ
2 or Fisher’s exact
test. We used unconditional multivariate logis-
tic regression analysis to examine the associa-
tion between the genetic polymorphism (domi-
nant  model:  heterozygotes+rare  homozygotes
vs. common homozygotes), and the risk of AAA.
The calculation of the Odds Ratio and its 95%
confidence  interval  was  performed  adjusting
the analysis for the other covariates. A type-I
error of 0.05 was used and all the tests were
two-tailed.
Results
Significant  differences  were  observed  in
demographic  factors  between  groups  of  AAA
patients  and  control  subjects,  including  age,
gender,  diabetes,  hypertension,  and  smoking
status (Table 1). Patients showed an elevated
percentage of males, higher prevalence of dia-
betes and hypertension compared to controls.
As expected, the group of AAA cases was older
than controls. The genotype distributions for
the HAS-1 polymorphism were consistent with
the Hardy-Weinberg equilibrium (p>0.05). The
simple analysis with a ˇ
2 test between the sta-
tus  (case/control)  and  HAS-1  genotypes
revealed  a  trend  in  the  co-dominant  model
(three  genotypes  separated,  p=0.077)  and  a
statistically significant association in the dom-
inant model (p=0.042, with Yates’ correction).
However,  the  multivariate  logistic  analysis,
after the adjustment for the above mentioned
covariates,  showed  that  the  association
between the risk of AAA and HAS-1 genotype
was not statistically significant, as reported in
Table 2. 
Discussion and Conclusions
Hyaluronan (HA) is an acidic glycosamino-
glycan made entirely of a repeating disaccha-
ride. Its molecular weight is often very high
mass, ranging from about 10
5-10
7 Da, depend-
ing upon the tissue, but it can also exist as
smaller fragments and oligosaccharides under
certain  physiological  or  pathological  condi-
tions. Originally thought to be an inert molec-
ular  “stuffing”  in  connective  tissues,  HA
mediates, by specific receptors, many impor-
tant  functional  activities  e.g.  cell  motility,
invasion  and  proliferation.  These  receptors
can also interact with smaller forms of HA.
Indeed, several studies suggest that fragmen-
tation of HA enhances its ability to activate
cell-signaling pathways.
9-11
HA is present in the extracellular matrix, on
the cell surface and inside the cell. HA func-
tions depend not only on its size but also upon
its cellular distribution. The notion that HA is
likely to take part in the development of vascu-
lar pathologies has been promoted by a num-
ber  of  observations,  which  show  marked
changes in the content and distribution of HA
in several arterial disease entities such as dia-
betic angiopathy, atherosclerosis and resteno-
sis. Early biochemical studies showed that HA
concentration  of  human  atherosclerotic
plaques generally decreases with increasing
severity of atherosclerosis.
12
Human  AAA  is  always  accompanied  by
advanced  atherosclerotic  lesions.  In  AAA,
matrix  molecules,  such  as  elastin,  collagen
and  glycosaminoglycans/proteoglycans  (GAG/
PG), are all responsible for the integrity of the
arterial wall. One of the most critical events
implicated in the development of AAA, is the
mechanical failure of collagen and elastin
13-15
and  although  many  investigations  have
focused  on  these  components,  our  under-
standing of the metabolism of GAG/PG in AAA
is extremely limited.
16,17
Some studies on AAA report a decrease in
the  amount  of  HA  that  may  be  attributed
either to HA-degrading enzymes released by
inflammatory cells or to an altered synthesis
of HA related to polymorphisms in the promot-
er  gene.  This  latter  hypothesis  could  be
explained by the existence of splicing variants
of HAS-1 that could activate specific inflam-
matory cell-signaling pathways and increase
the protease production. 
In our study, a significant difference in the
genotype distribution of HAS-1 polymorphism
in AAA patients, compared to controls was not
seen. 
We  are  aware  that  the  present  study  is
underpowered,  however,  our  results  show
implicitly that the effect of the polymorphism
is too weak to confer a decisive risk in the eti-
ology of AAA. Probably, other polymorphisms
within HAS-1 could have a stronger impact on
the risk of the disease.
Table 2. Adjusted odd ratios for the covariates reported in Table 1. Cellular proliferation
HAS1 genotypes Cases Controls Odds ratio 95% lower limit 95% upper limit p
Common homozygotes 117 107 1
Heterozygotes 21 41
Rare homozygotes 30 0.65 0.13 3.15 0.58
95% Odds ratio (OR) and 95% confidence intervals for the risk of AAA. OR is adjusted for the covariates reported in Table 1. Dominant model: the rare homozygotes are pooled with the heterozygotes.
Reference category: common homozygotes.
Table 1. Demographic data.Cellular proliferation
Control (N=156) AAA (N=146) p
Age (years) 55 (50-69) 74 (30-94) <0.0001
a
BMI (kg/m
2) 26.4±2.8 27.1±3.5 0.074
a
Male sex 107 139 <0.0001
b
Hypertension 16 56 <0.0001
b
Hypercholesterolemia 22 25 0.94
b
Diabetes 2 10 0.04
c
S 18 S 28
Smoking status EX 30 EX 60 <0.0001
b
NS 49 NS 25
AAA: abdominal aortic aneurysm; BMI, body mass index; S: smokers; EX: ex-smokers; NS: no smokers. Age data represent median and
range. BMI data represent mean±SD. aStudent’s t test; bχ
2 test; cFisher’s exact test.Article
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